Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.

@article{Pietrantonio2017HeterogeneityOA,
  title={Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.},
  author={Filippo Pietrantonio and Claudio Vernieri and Giulia Siravegna and Alessia Mennitto and Rosa Berenato and Federica Perrone and Annunziata Gloghini and Elena Tamborini and Sara Lonardi and Federica Morano and Benedetta Picciani and Adele Busico and Chiara Costanza Volpi and Antonia Martinetti and Francesca Battaglin and Ilaria Bossi and Alessio Pellegrinelli and Massimo Milione and Chiara Cremolini and Maria Di Bartolomeo and Alberto Bardelli and Filippo de Braud},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2017},
  volume={23 10},
  pages={2414-2422}
}
Purpose: Even if RAS-BRAF wild-type and HER2/MET-negative metastatic colorectal cancer (mCRC) patients frequently respond to anti-EGFR mAbs, acquired resistance almost invariably occurs. Mechanisms of resistance to EGFR blockade include the emergence of KRAS, NRAS, and EGFR extracellular domain mutations as well as HER2/MET alterations. However, these findings derive from retrospective studies that analyzed one single resistance mechanism at a time; moreover, it is still unclear how molecular… CONTINUE READING
Highly Cited
This paper has 24 citations. REVIEW CITATIONS

From This Paper

Figures and tables from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Emergence of RAS or EGFR extracellular domain mutations and duration of response to EGFR blockade in colorectal cancer

  • B Van Emburgh, S Arena, G Siravegna, L Lazzari, G Crisafulli, G. Corti
  • Nat Commun,
  • 2016
1 Excerpt

Impact of primary (1o) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer

  • AP Venook, D Niedzwiecki, F Innocenti, B Fruth, C Greene, BH O'Neil
  • (mCRC): Analysis of CALGB/SWOG
  • 2016
1 Excerpt

Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors

  • H Hurwitz, JD Hainsworth, C Swanton, EA Perez, C Sweeney, HA Burris
  • 2016
1 Excerpt

Similar Papers

Loading similar papers…